Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Source Summary

Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv